Ding Haiyang, Wang Chuanguang, Ghorbani Hamzeh, Yang Sufang, Stepanyan Harutyun, Zhang Guodao, Zhou Nan, Wang Wu
Department of Anesthesia, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China.
Department of Anesthesia, Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, China.
Heliyon. 2024 May 28;10(11):e32127. doi: 10.1016/j.heliyon.2024.e32127. eCollection 2024 Jun 15.
This scientific review involves a sequential analysis of randomized trial research focused on the incidence of shivering in patients undergoing cardiac surgery. The study conducted a comprehensive search of different databases, up to the end of 2020. Only randomized trials comparing magnesium administration with either placebo or no treatment in patients expected to experience shivering were included. The primary objective was to evaluate shivering occurrence, distinguishing between patients receiving general anesthesia and those not. Secondary outcomes included serum magnesium concentrations, intubation time, post-anesthesia care unit stay, hospitalization duration, and side effects. Data collection included patient demographics and various factors related to magnesium administration.
This scientific review analyzed 64 clinical trials meeting inclusion criteria, encompassing a total of 4303 patients. Magnesium was administered via different routes, primarily intravenous, epidural, and intraperitoneal, and compared against placebo or control. Data included demographics, magnesium dosage, administration method, and outcomes. Heterogeneity was assessed using the I statistic. Some studies were excluded due to unavailability of data or non-responsiveness from authors.
and discussion: Out of 2546 initially identified articles, 64 trials were selected for analysis. IV magnesium effectively reduced shivering, with epidural and intraperitoneal routes showing even greater efficacy. IV magnesium demonstrated cost-effectiveness and a favorable safety profile, not increasing adverse effects. The exact dose-response relationship of magnesium remains unclear. The results also indicated no significant impact on sedation, extubation time, or gastrointestinal distress. However, further research is needed to determine the optimal magnesium dose and to explore its potential effects on blood pressure and heart rate, particularly regarding pruritus prevention.
This study highlights the efficacy of intravenous (IV) magnesium in preventing shivering after cardiac surgery. Both epidural and intraperitoneal routes have shown promising results. The safety profile of magnesium administration appears favorable, as it reduces the incidence of shivering without significantly increasing costs. However, further investigation is required to establish the ideal magnesium dosage and explore its potential effects on blood pressure, heart rate, and pruritus prevention, especially in various patient groups.
本科学综述对聚焦于心脏手术患者寒战发生率的随机试验研究进行了序贯分析。该研究对不同数据库进行了全面检索,截至2020年底。仅纳入了在预期会发生寒战的患者中比较镁剂给药与安慰剂或未治疗的随机试验。主要目的是评估寒战的发生情况,区分接受全身麻醉的患者和未接受全身麻醉的患者。次要结局包括血清镁浓度、插管时间、麻醉后监护病房停留时间、住院时间和副作用。数据收集包括患者人口统计学信息以及与镁剂给药相关的各种因素。
本科学综述分析了64项符合纳入标准的临床试验,共涉及4303例患者。镁剂通过不同途径给药,主要是静脉内、硬膜外和腹腔内给药,并与安慰剂或对照进行比较。数据包括人口统计学信息、镁剂剂量、给药方法和结局。使用I统计量评估异质性。由于数据不可用或作者无回应,一些研究被排除。
在最初识别的2546篇文章中,选择了64项试验进行分析。静脉注射镁剂可有效减少寒战,硬膜外和腹腔内给药途径显示出更高的疗效。静脉注射镁剂具有成本效益且安全性良好,不会增加不良反应。镁的确切剂量 - 反应关系仍不清楚。结果还表明对镇静、拔管时间或胃肠道不适无显著影响。然而,需要进一步研究以确定最佳镁剂剂量,并探索其对血压和心率的潜在影响,特别是在预防瘙痒方面。
本研究强调了静脉注射(IV)镁剂在预防心脏手术后寒战方面的疗效。硬膜外和腹腔内给药途径均显示出有前景的结果。镁剂给药的安全性似乎良好,因为它降低了寒战发生率且未显著增加成本。然而,需要进一步研究以确定理想的镁剂剂量,并探索其对血压、心率和瘙痒预防的潜在影响,特别是在不同患者群体中。